Pharmafile Logo

Time for a new language for asthma?

November 23, 2016 | asthma, market research 


Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines. A comprehensive market research study has recently been conducted among patients across Asia, in order to try to understand patient perceptions of asthma control and confirms that 50% of patients are uncontrolled. Because patients lack an understanding of what control means, many patients considerably overestimate the extent to which they are successfully managing their condition.

Read the article: http://www.researchpartnership.com/news/2016/10/article-time-for-a-new-language-for-asthma/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...

Webcast: AI in MRX: Harnessing the power of AI + people

Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.